Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07313202) titled 'Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance' on Dec. 17, 2025.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fujian Cancer Hospital
Condition:
Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE
Intervention:
Drug: Ivarmacitinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: December 10, 2025
Target Sample Size: 72
...